Table 1.
Basal clinical characteristics in SGLT2i and control group
| Variable | SGLT2i (n = 30) | Control (n = 22) | p value |
|---|---|---|---|
| Female, n (%) | 13 (43%) | 10 (45%) | 0.88 |
| Age (years) | 65.7 ± 8.7 | 68.2 ± 8.5 | 0.32 |
| Arterial hypertension | 18 (60%) | 16 (73%) | 0.34 |
| Smokers | 6 (20%) | 1 (4%) | 0.22 |
| Dyslipidaemia | 16 (53%) | 12 (54%) | 0.93 |
| Coronary disease | 3 (10%) | 1 (4%) | 0.33 |
| Metformin | 23 (77%) | 18 (82%) | 0.74 |
| DPP4 inhibitors | 8 (27%) | 7 (32%) | 0.68 |
| Insulin | 9 (30%) | 5 (23%) | 0.56 |
| RAAS inhibitors | 21 (70%) | 17 (77%) | 0.56 |
| Beta-blockers | 3 (10%) | 2 (9%) | 0.89 |
| Aldosterone antagonist | 2 (7%) | 0 (0%) | 0.50 |
| GF ≥ 60 ml/min/1.73 m2 | 12 (43%) | 11 (50%) | 0.24 |
| Glycated haemoglobin | 7.78 ± 0.94 | 6.97 ± 0.44 | 0.002 |
| Diabetes duration (months) | 87 ± 97 | 128 ± 105 | 0.14 |
| BMI (kg/m2) | 30.5 ± 6.8 | 28.9 ± 4.7 | 0.33 |
| GF (ml/min/1.73 m2) | 92.6 ± 40.8 | 86.7 ± 28.9 |
DPP4 dipeptidyl peptidase-4, RAAS renin-angiotensin-aldosterone system, GF glomerular filtration, BMI Body Mass Index